Walk a Mile in My Shoes

The Itch Is More Than Skin Deep: What the Changing Landscape of Primary Biliary Cholangitis (PBC) Means for Your Patients and You 

Walk a Mile in My Shoes 

ReachMD Healthcare Image
Media formats available:
  • Overview

    Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
    Director, Liver Institute Northwest
    Seattle, WA

    Dr. Kowdley has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: 89Bio, CymaBay Therapeutics, Genfit, Gilead, GlaxoSmithKline, Hanmi, HighTide, Intercept, Ipsen, Madrigal, Mirum, NGM, Pfizer, Pliant, and Viking
    Receives Royalities: UpToDate
    Consulting fees: 89Bio, AbbVie, Calliditas Therapeutics, CymaBay Therapeutics, Gilead, Genfit, Gilead, Inipharm, Intercept, Madrigal, Mirum, NGM, and Pliant

    Marlyn Mayo, MD
    Professor of Internal Medicine
    UT Southwestern Medical Center
    Dallas, TX

    Dr. Mayo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: CymaBay Therapeutics, Genfit, GlaxoSmithKline, Intercept, Intra-Sana Laboratories, Ipsen, Mallinckrodt, Mirum, Target RWE
    Consulting Fees: CymaBay Therapeutics, GlaxoSmithKline, Ipsen, Mallinckrodt

    Atoosa Rabiee, MD
    Chief of Transplant Services
    Washington DC VA Medical Center
    Washington, DC

    No relevant financial relationships to report.

    Reviewers/Content Planners/Authors:

    • Jennifer Brutsche has nothing to disclose. 
    • Cindy Davidson has nothing to disclose.
    • John Maeglin has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Katie Sheridan has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Susan Smith, MN, PhD has ownership interest in Hepion Pharmaceuticals.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Compare the historic and evolving phenotype of primary biliary cholangitis (PBC)
    • Differentiate between the goals of pharmacologic therapy for PBC and the goals of patients with PBC
    • Determine the appropriate treatment plan for a patient who does not show a response to first-line therapy for PBC 
    • Summarize data from late-stage clinical trials of novel agents for the treatment of PBC
  • Target Audience

    This activity is designed to meet the educational needs of gastroenterologists and hepatologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hours/.1 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is UAN JA0006235-0000-23-082-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Ipsen Biopharmaceuticals, Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free